Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid.
bullous pemphigoid
eosinophil
galectin- 9
autoimmune disease
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
23 Mar 2021
23 Mar 2021
Historique:
pubmed:
20
2
2021
medline:
24
6
2021
entrez:
19
2
2021
Statut:
epublish
Résumé
Massive recruitment of eosinophils into the dermis is a hallmark of bullous pemphigoid pathogenesis. Identifying the chemoattractant(s) guiding eosinophils into the skin in bullous pemphigoid is a prerequisite to thera-peutic targeting of eosinophil recruitment. Galectin -9 is a potent chemoattractant for eosinophils, but its potential role in bullous pemphigoid is unknown. The aim of this study was to determine the expression levels of galectin-9 in serum and skin of patients with bullous pemphigoid. Galectin-9 levels were significantly elevated in serum of patients with bullous pemphigoid compared with age- and sex-matched controls, but did not correlate with disease activity assessed with the Bullous Pemphigoid Disease Area Index. Galectin-9 expression was also increased in lesional skin of patients with bullous pemphigoid, and was expressed predominantly in eosinophils, neutrophils and keratinocytes. In conclusion, these results support the notion that galectin-9 may play a role in the patho-genesis of bullous pemphigoid.
Identifiants
pubmed: 33606034
doi: 10.2340/00015555-3771
pmc: PMC9366699
doi:
Substances chimiques
Galectins
0
Immunologic Factors
0
LGALS9 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00419Références
J Immunol. 2002 Feb 15;168(4):1961-7
pubmed: 11823532
J Leukoc Biol. 2012 Feb;91(2):207-15
pubmed: 22058421
Allergy. 2020 Mar;75(3):669-672
pubmed: 31230371
Arthritis Rheumatol. 2018 Jul;70(7):1089-1101
pubmed: 29481735
JCI Insight. 2019 Aug 8;4(15):
pubmed: 31391346
Front Med (Lausanne). 2018 Nov 08;5:306
pubmed: 30467542
Arthritis Rheumatol. 2019 Aug;71(8):1377-1390
pubmed: 30861625
J Biol Chem. 2009 Nov 20;284(47):32344-52
pubmed: 19776007
Medicine (Baltimore). 2019 Aug;98(35):e16924
pubmed: 31464928
Clin Immunol. 2006 Aug;120(2):220-31
pubmed: 16782408
Sci Rep. 2017 Jul 6;7(1):4833
pubmed: 28684769
Trends Immunol. 2011 Oct;32(10):452-60
pubmed: 21839682
Allergy. 2019 Sep;74(9):1769-1779
pubmed: 31034608
Int J Mol Sci. 2019 Aug 19;20(16):
pubmed: 31430907
Arch Dermatol Res. 1996 Jun;288(7):353-7
pubmed: 8818181
Int Arch Allergy Immunol. 2010;151(4):308-17
pubmed: 19851072
Semin Immunopathol. 2019 Nov;41(6):645-654
pubmed: 31732776
Clin Immunol. 2009 Dec;133(3):382-92
pubmed: 19800850
Front Immunol. 2017 Apr 27;8:484
pubmed: 28496445
Nat Rev Immunol. 2013 Jan;13(1):9-22
pubmed: 23154224
J Biol Chem. 1998 Jul 3;273(27):16976-84
pubmed: 9642261
Front Med (Lausanne). 2018 Jul 10;5:201
pubmed: 30042946
Mol Med. 2017 Feb;22:918-926
pubmed: 27999842
J Immunol. 2002 Oct 1;169(7):3987-92
pubmed: 12244200
Clin Immunol. 2008 Apr;127(1):78-88
pubmed: 18282810
Int Arch Allergy Immunol. 2002 May;128(1):42-50
pubmed: 12037400
J Dermatol. 2015 Jul;42(7):723-6
pubmed: 25899120
Int Arch Allergy Immunol. 2010;153(3):294-302
pubmed: 20484929
J Immunol Res. 2018 Nov 27;2018:9473243
pubmed: 30599005
Int J Immunopathol Pharmacol. 1999 May-Aug;12(2):55-61
pubmed: 12783647
J Endocrinol. 2009 May;201(2):169-84
pubmed: 19155286
Melanoma Res. 2016 Oct;26(5):429-41
pubmed: 27455380
J Clin Invest. 2018 May 1;128(5):1873-1887
pubmed: 29611821
Ann Rheum Dis. 2018 Dec;77(12):1810-1814
pubmed: 30185417
J Allergy Clin Immunol. 2020 Apr;145(4):1145-1147
pubmed: 32272983
J Autoimmun. 2019 Jan;96:104-112
pubmed: 30219389